Element Biosciences created a high-throughput benchtop device that can deliver a whole genome for $100 – half the price of ...

For 50 years, scientists at the San Diego Zoo have been collecting and storing cells from rare and endangered species in its Frozen Zoo with an eye to the future. The future is here. The San Diego Zoo ...

Grail continues facing significant challenges as its stock plummeted over 45% after its landmark NHS-Galleri trial failed to ...

Genomics and synthetic biology are reshaping healthcare, as rapid DNA sequencing advances power personalized medicine and ...

The renewed and expanded agreements provide improved commercial conditions, including more competitive pricing, optimized contractual terms, and enhanced supply security. These improvements will ...

Monib Zirvi Ph.D. ’96 M.D. ’00 on Jan. 23 filed a petition asking the high court to review his malpractice claim alleging that Akin Gump, a prominent law firm who represented Cornell in litigation ...

Grail’s stock was the Nasdaq’s biggest loser Friday, after a key trial of its Galleri early-detection cancer test failed to meet its primary endpoint.

The human genome is made up of 3 billion letters of DNA (A, T, C and G). Whole genome sequencing is a technique that is used ...

Retrotransposons are pivotal in human genome evolution, driving structural variation and regulatory innovation while influencing health and disease.

MENLO PARK, Calif., Feb. 19, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial ...

The fund underperformed the MSCI ACWI ex-US Growth Index but outperformed the Morningstar Foreign Large Growth peer group ...

The Life Science division of Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, today announced the launch of its Lyophilized NGS ...